Overview
On 29 May 2019, orphan designation (EU/3/19/2162) was granted by the European Commission to Pharma Gateway AB, Sweden, for emixustat hydrochloride for the treatment of Stargardt’s disease.
Key facts
Active substance |
Emixustat hydrochloride
|
Intended use |
Treatment of Stargardt's disease
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2162
|
Date of designation |
29/05/2019
|
Sponsor |
Pharma Gateway AB |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: